Go Pro
NASDAQ:TNXP

Tonix Pharmaceuticals Q3 2025 Earnings Report

Tonix Pharmaceuticals logo
$9.70 -0.54 (-5.27%)
Closing price 04:00 PM Eastern
Extended Trading
$9.82 +0.12 (+1.22%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tonix Pharmaceuticals EPS Results

Actual EPS
-$3.59
Consensus EPS
-$3.59
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Tonix Pharmaceuticals Revenue Results

Actual Revenue
$3.29 million
Expected Revenue
$2.30 million
Beat/Miss
Beat by +$990.00 thousand
YoY Revenue Growth
N/A

Tonix Pharmaceuticals Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Monday, November 10, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Tonix Pharmaceuticals' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Tonix Pharmaceuticals Earnings Headlines

Tonix Pharmaceuticals Holding Corp (TNXP)
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.tc pixel
See More Tonix Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tonix Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tonix Pharmaceuticals and other key companies, straight to your email.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals (NASDAQ:TNXP) is a biopharmaceutical company focused on developing therapies and vaccines for conditions involving the central nervous system, immunology, and infectious diseases. The company’s programs use a range of approaches, including small-molecule medicines, biologics, vaccines, and intranasal therapies.

Tonix’s development portfolio has included TNX-102 SL, a sublingual formulation of cyclobenzaprine investigated for fibromyalgia and other pain-related conditions. The company has also pursued candidates such as TNX-1900, an intranasal oxytocin-based therapy being studied for neuropsychiatric and metabolic disorders, as well as vaccine programs including TNX-801, a vaccine candidate for smallpox and mpox.

Founded in 2007, Tonix Pharmaceuticals is headquartered in Chatham, New Jersey. The company’s research and development activities are primarily conducted in the United States, with programs intended for potential use in global markets. Seth Lederman, M.D., is the company’s founder, chairman, and chief executive officer.

View Tonix Pharmaceuticals Profile